Top Markets
Coin of the day
Adagio Therapeutics, Inc. Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc.

ADGI
株式のランク #16450
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily... Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily focused on the discovery, development, and subsequent commercialization of antibody-based therapeutics designed to combat infectious diseases across the United States. Its most advanced product candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical trials. This antibody is being evaluated for both the treatment and prevention of coronavirus disease. Adagio Therapeutics also engages in strategic collaborations. It partners with Adimab, LLC to facilitate the discovery and optimization of novel proprietary antibodies. Furthermore, the company works with the Scripps Research Institute on research initiatives aimed at identifying vaccine candidates that could prevent, diagnose, or treat influenza and beta coronaviruses. Founded in 2020, Adagio Therapeutics maintains its headquarters in Waltham, Massachusetts.
株価
$4.64
最終同期: 2022-09-12
時価総額
$293.43M
変化(1日)
0.87%
変化(1年)
0.00%
US
取引 Adagio Therapeutics, Inc. (ADGI)

カテゴリー

Adagio Therapeutics, Inc.(ADGI)の配当利回りの履歴
Adagio Therapeutics, Inc.(銘柄コード: ADGI)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Adagio Therapeutics, Inc.(ADGI)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)